Skip to content

Study · Animal study (in vivo) · rat · 1994

4 results

Differential metabolism of Tyr-MIF-1 and MIF-1 in rat and human plasma.

Kastin AJ, Hahn K, Erchegyi J, Zadina JE, Hackler L, Palmgren M, Banks WA

Biochemical pharmacology1 Feb 1994Cited by 16 (Europe PMC)

PMID7907473 (opens in a new tab)DOI10.1016/0006-2952(94)90133-3 (opens in a new tab)PepBankPUB-07907473
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, intravenously injected tritiated MIF‑1 had a short blood disappearance half-time but persisted longer than Tyr-MIF‑1.

    In plain wordsIn rats, injected labeled MIF‑1 disappeared rapidly from blood but lasted longer than Tyr-MIF‑1.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreaseBlood disappearance
    Study

    ratn: not reported in source

    Comparator
    Tyr-MIF-1
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    Intravenous injection of the tritiated peptides into rats showed short half-time disappearances; again, MIF-1 persisted in blood longer than Tyr-MIF-1.
  2. 02LabIn vitro (cell-free)Pharmacokinetics

    In rat plasma, tritiated MIF‑1 persisted slightly longer than Tyr-MIF‑1, but more than half degraded within 5 min.

    In plain wordsIn lab tests with rat plasma, labeled MIF‑1 lasted slightly longer than Tyr-MIF‑1 but degraded rapidly.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreasePlasma degradation
    Study

    ratn: not reported in source

    Rat plasma
    Comparator
    Tyr-MIF-1
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Degraded fraction
    > 50%
    rat plasma within 5 min

    Source sentences

    Summary
    In rat plasma, more than half of the intact Tyr-MIF-1 and MIF-1 was degraded within 5 min, in contrast to the 5 days required for 50% degradation of MIF-1 in human plasma at 37 degrees.
    1 context sentence
    Summary · context
    Degradation of Tyr-MIF-1 was rapid in the plasma from both species, in contrast to the slightly delayed degradation of MIF-1 in rat plasma and the extremely prolonged persistence of MIF-1 in human plasma.
  3. 03LabIn vitro (cell-free)Pharmacokinetics

    In human plasma, tritiated MIF‑1 required 5 days for 50% degradation at 37 degrees, showing prolonged persistence.

    In plain wordsIn lab tests, labeled MIF‑1 persisted much longer in human plasma than Tyr-MIF‑1 or MIF‑1 in rat plasma.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    IncreasePlasma degradation
    Study

    humann: not reported in source

    Human plasma
    Comparator
    Tyr-MIF-1 and MIF-1 in rat plasma
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Time to 50% degradation
    5 days
    human plasma at 37 degrees

    Source sentences

    Summary
    In rat plasma, more than half of the intact Tyr-MIF-1 and MIF-1 was degraded within 5 min, in contrast to the 5 days required for 50% degradation of MIF-1 in human plasma at 37 degrees.

Studies that did not test the peptide alone1

In this study, MIF-1 (Pro-Leu-Gly-NH2) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MIF-1 (Pro-Leu-Gly-NH2).

  1. 04LabNot a test of MIF-1 (Pro-Leu-Gly-NH2) aloneIn vitro (cell-free)Pharmacokinetics

    In plasma incubation, Tyr-Pro rather than MIF‑1 was the predominant degradation product of tritiated Tyr-MIF‑1.

    In plain wordsIn lab tests, labeled Tyr-MIF‑1 mainly formed Tyr-Pro rather than MIF‑1.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    Not applicableMIF-1 formation from Tyr-MIF-1
    Study

    n: not reported in source

    Plasma incubation
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Incubation of Tyr-MIF-1 tritiated at the Pro under the same conditions with and without Tyr-MIF-1 tritiated at the Tyr showed that Tyr-Pro, not MIF-1, was the predominant degradation product of Tyr-MIF-1.

    In this study, MIF-1 (Pro-Leu-Gly-NH2) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MIF-1 (Pro-Leu-Gly-NH2).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.